MX347913B - Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina. - Google Patents

Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina.

Info

Publication number
MX347913B
MX347913B MX2013010969A MX2013010969A MX347913B MX 347913 B MX347913 B MX 347913B MX 2013010969 A MX2013010969 A MX 2013010969A MX 2013010969 A MX2013010969 A MX 2013010969A MX 347913 B MX347913 B MX 347913B
Authority
MX
Mexico
Prior art keywords
cyclopropylamines
lsd1 inhibitors
lsd1
relates
inhibitors
Prior art date
Application number
MX2013010969A
Other languages
English (en)
Other versions
MX2013010969A (es
Inventor
Jiri Kasparec
William Henry Miller
Neil W Johnson
Meagan B Rouse
Xinrong Tian
Dominic Suarez
Original Assignee
Glaxosmithkline Intellectual Property (No 2) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property (No 2) Ltd filed Critical Glaxosmithkline Intellectual Property (No 2) Ltd
Publication of MX2013010969A publication Critical patent/MX2013010969A/es
Publication of MX347913B publication Critical patent/MX347913B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/36—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing at least two amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Abstract

Esta invención se relaciona al uso de derivados de ciclopropilamina para la modulación, en particular la inhibición de la actividad de desmetilasa 1 específica de Lisina (LSD1); convenientemente, la presente invención se relaciona al uso de ciclopropilaminas en el tratamiento de cáncer.
MX2013010969A 2011-03-25 2012-03-26 Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina. MX347913B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161467524P 2011-03-25 2011-03-25
US201161514140P 2011-08-02 2011-08-02
US201261594012P 2012-02-02 2012-02-02
PCT/US2012/030552 WO2012135113A2 (en) 2011-03-25 2012-03-26 Cyclopropylamines as lsd1 inhibitors

Publications (2)

Publication Number Publication Date
MX2013010969A MX2013010969A (es) 2014-03-27
MX347913B true MX347913B (es) 2017-05-17

Family

ID=46932271

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010969A MX347913B (es) 2011-03-25 2012-03-26 Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina.

Country Status (22)

Country Link
US (4) US8853408B2 (es)
EP (1) EP2688568B1 (es)
JP (1) JP5813855B2 (es)
KR (1) KR101884493B1 (es)
CN (1) CN103857393B (es)
AU (1) AU2012236868B2 (es)
BR (1) BR112013024502B1 (es)
CA (1) CA2831143C (es)
CL (1) CL2013002737A1 (es)
CO (1) CO6771447A2 (es)
CR (1) CR20130550A (es)
DO (1) DOP2013000211A (es)
EA (1) EA023143B1 (es)
ES (1) ES2742805T3 (es)
IL (1) IL228248A (es)
MA (1) MA35096B1 (es)
MX (1) MX347913B (es)
MY (1) MY165620A (es)
PE (1) PE20141322A1 (es)
SG (1) SG193241A1 (es)
WO (1) WO2012135113A2 (es)
ZA (1) ZA201306580B (es)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
MX338041B (es) 2009-09-25 2016-03-30 Oryzon Genomics Sa Inhibidores de demetilasa-1 especificos de lisina y su uso.
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
US9186337B2 (en) 2010-02-24 2015-11-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
KR101794020B1 (ko) 2010-04-19 2017-11-06 오리존 지노믹스 에스.에이. 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도
US9181198B2 (en) 2010-07-29 2015-11-10 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
WO2012013727A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
AU2012293223B2 (en) 2011-08-09 2017-03-02 Takeda Pharmaceutical Company Limited Cyclopropaneamine compound
CN107266345B (zh) 2011-10-20 2021-08-17 奥瑞泽恩基因组学股份有限公司 作为lsd1抑制剂的(杂)芳基环丙胺化合物
RS58475B1 (sr) * 2011-10-20 2019-04-30 Oryzon Genomics Sa Jedinjenja (hetero)aril ciklopropilamina kao lsd1 inhibitori
SI3023415T1 (en) 2012-10-02 2018-01-31 Gilead Sciences, Inc. Histone demethylase inhibitors
US9751885B2 (en) 2012-10-12 2017-09-05 Takeda Pharmaceutical Company Limited Cyclopropanamine compound and use thereof
EP2740474A1 (en) 2012-12-05 2014-06-11 Instituto Europeo di Oncologia S.r.l. Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
BR112015020650A2 (pt) 2013-02-27 2017-07-18 Epitherapeutics Aps inibidores de histona demetilases
WO2014194280A2 (en) * 2013-05-30 2014-12-04 The Board of Regents of the Nevada System of Higher Education on behalf of the University of Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells
ES2897946T3 (es) * 2013-07-25 2022-03-03 Dong A St Co Ltd Método para preparar un derivado de benzamida, intermedio novedoso utilizado en la preparación de la benzamida y método para preparar un intermedio novedoso
BR112016002496B1 (pt) * 2013-08-06 2022-07-12 Imago Biosciences Inc. Composto e composição farmacêutica
ME03580B (me) 2014-02-13 2020-07-20 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
ES2672797T3 (es) 2014-02-13 2018-06-18 Incyte Corporation Ciclopropilaminas como inhibidores de LSD1
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
CA2939082C (en) * 2014-02-13 2022-06-07 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
CN104042616B (zh) * 2014-02-20 2016-08-24 复旦大学附属眼耳鼻喉科医院 赖氨酸特异性去甲基化酶1抑制剂的应用
UA122205C2 (uk) 2014-04-11 2020-10-12 Такеда Фармасьютікал Компані Лімітед Сполука циклопропанаміну та її застосування
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
EA201790154A1 (ru) 2014-08-27 2017-08-31 Джилид Сайэнс, Инк. Соединения и способы для ингибирования гистоновых деметилаз
WO2016055935A1 (en) * 2014-10-06 2016-04-14 Glaxosmithkline Intellectual Property (No.2) Limited Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
EA039196B1 (ru) * 2014-10-08 2021-12-16 Инсайт Корпорейшн Циклопропиламины в качестве ингибиторов lsd1
EP3250552B1 (en) * 2015-01-30 2019-03-27 Genentech, Inc. Therapeutic compounds and uses thereof
KR102626978B1 (ko) 2015-02-12 2024-01-18 이마고 바이오사이언시즈 인코포레이티드 질환 치료를 위한 kdm1a 저해제
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
US10526287B2 (en) 2015-04-23 2020-01-07 Constellation Pharmaceuticals, Inc. LSD1 inhibitors and uses thereof
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
US20180284095A1 (en) 2015-06-12 2018-10-04 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
CR20180152A (es) * 2015-08-12 2018-08-09 Incyte Corp Sales de un inhibidor de lsd1
EP3341353A1 (en) 2015-08-27 2018-07-04 Genentech, Inc. Therapeutic compounds and methods of use thereof
US10059668B2 (en) 2015-11-05 2018-08-28 Mirati Therapeutics, Inc. LSD1 inhibitors
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
WO2017097865A1 (en) * 2015-12-07 2017-06-15 Istituto Europeo Di Oncologia Combination of caloric restriction (cr) or igf1/insulin receptor inhibitor with lsd1 inhibitor
WO2017116558A1 (en) * 2015-12-29 2017-07-06 Mirati Therapeutics, Inc. Lsd1 inhibitors
EP3397756B1 (en) 2015-12-30 2023-03-08 Novartis AG Immune effector cell therapies with enhanced efficacy
KR102646126B1 (ko) 2016-03-15 2024-03-11 오리존 지노믹스 에스.에이. 혈액 악성 종양의 치료를 위한 lsd1 억제제의 조합물
KR20230042756A (ko) 2016-03-15 2023-03-29 오리존 지노믹스 에스.에이. 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물
JP2019512546A (ja) * 2016-03-16 2019-05-16 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｋｄｍ１ａ標的会合を決定するための方法、およびそれに有用な化学プローブ
CN107200706A (zh) * 2016-03-16 2017-09-26 中国科学院上海药物研究所 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
MX2018012901A (es) 2016-04-22 2019-06-06 Incyte Corp Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1).
CN107459476B (zh) * 2016-06-03 2022-06-24 中国科学院上海药物研究所 反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途
SG11201710199PA (en) 2016-06-10 2018-05-30 Oryzon Genomics Sa Methods of treating multiple sclerosis
WO2018020366A1 (en) 2016-07-26 2018-02-01 Glaxosmithkline Intellectual Property (No.2) Limited Crystalline (r)-mandelate salt of (1r,2s)-2-phenylcyclopropylamine
SG10201610038SA (en) * 2016-07-29 2017-12-28 Apple Inc Systems and methods for management of asymmetrical multi-tapped battery packs
US11390590B2 (en) 2016-08-16 2022-07-19 Imago Biosciences, Inc. Methods and processes for the preparation of KDM1A inhibitors
CA3039853A1 (en) 2016-10-17 2018-04-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3535420A1 (en) 2016-11-03 2019-09-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
US20190256929A1 (en) 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
EP3551178A1 (en) 2016-12-09 2019-10-16 Constellation Pharmaceuticals, Inc. Markers for personalized cancer treatment with lsd1 inhibitors
EP3575285A4 (en) * 2017-01-24 2020-08-12 Medshine Discovery Inc. LSD1 INHIBITOR AND MANUFACTURING METHOD AND APPLICATION OF IT
EP3601273B1 (en) 2017-03-24 2021-12-01 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
WO2018197583A1 (en) 2017-04-26 2018-11-01 Istituto Europeo Di Oncologia Use of a combinational therapy of lsd1 inhibitors with p21 activators in the treatment of cancer
MX2019014104A (es) 2017-05-26 2020-02-07 Taiho Pharmaceutical Co Ltd Compuesto novedoso de bifenilo o sal del mismo.
FI3632443T3 (fi) 2017-05-26 2023-08-23 Taiho Pharmaceutical Co Ltd Kasvainkasvua ehkäisevän vaikutuksen tehostaja, jossa käytetään bifenyyliyhdistettä
AU2018276611B2 (en) 2017-05-31 2022-01-06 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
KR20180134675A (ko) * 2017-06-09 2018-12-19 한미약품 주식회사 시클로프로필아민 유도체 화합물 및 이의 용도
JP2020152641A (ja) * 2017-07-07 2020-09-24 国立研究開発法人理化学研究所 リジン特異的脱メチル化酵素１阻害活性を有する新規化合物、その製造方法及びその用途
SG11202000077RA (en) 2017-08-03 2020-02-27 Oryzon Genomics Sa Methods of treating behavior alterations
AR112900A1 (es) 2017-09-13 2019-12-26 Hanmi Pharm Ind Co Ltd Compuesto derivado de pirazol y uso de este
WO2019068326A1 (en) 2017-10-05 2019-04-11 Université D'aix-Marseille INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
KR20190040763A (ko) 2017-10-11 2019-04-19 한미약품 주식회사 피라졸로피리딘 유도체 화합물 및 이의 용도
KR20190040783A (ko) 2017-10-11 2019-04-19 한미약품 주식회사 라이신 특이적 데메틸라제-1 억제제로서의 피라졸 유도체
US11685782B2 (en) 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
WO2019109095A1 (en) * 2017-12-01 2019-06-06 Beth Israel Deaconess Medical Center, Inc. Arsenic trioxide and retinoic acid compounds for treatment of idh2-associated disorders
CN108107199B (zh) * 2017-12-21 2019-02-12 广州市进德生物科技有限公司 一种酶化学发光法测定尿酸的检测试剂盒
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2019217972A1 (en) 2018-05-11 2019-11-14 Imago Biosciences, Inc. Kdm1a inhibitors for the treatment of disease
US20210317096A1 (en) * 2018-07-20 2021-10-14 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Salt of lsd1 inhibitor and a polymorph thereof
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
US11649245B2 (en) 2018-09-13 2023-05-16 Helioeast Pharmaceutical Co., Ltd. Cyclopropylamine compound as LSD1 inhibitor and use thereof
CN112672994B (zh) * 2018-09-13 2022-09-13 南昌弘益药业有限公司 作为lsd1抑制剂的杂螺环类化合物及其应用
US20220024891A1 (en) * 2018-12-04 2022-01-27 The Board Of Regents Of The University Of Texas System Therapeutics targeting mutant adenomatous polyposis coli (apc) for the treatment of cancer
WO2020138398A1 (ja) * 2018-12-28 2020-07-02 国立研究開発法人理化学研究所 リジン特異的脱メチル化酵素１を阻害する新規化合物、その製造方法及びその用途
AU2020216034A1 (en) 2019-02-01 2021-08-19 Hanmi Pharm. Co., Ltd. Imidazopyridine derivative compounds and use of same
WO2020159285A1 (ko) 2019-02-01 2020-08-06 한미약품 주식회사 이미다조피리딘 유도체 화합물 및 이의 용도
BR112021016064A2 (pt) 2019-03-20 2021-10-05 Oryzon Genomics, S.A. Métodos de tratamento do transtorno de personalidade borderline
WO2020188089A1 (en) 2019-03-20 2020-09-24 Oryzon Genomics, S.A. Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
EP3994280A1 (en) 2019-07-05 2022-05-11 Oryzon Genomics, S.A. Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors
WO2021058024A1 (zh) * 2019-09-29 2021-04-01 南京明德新药研发有限公司 Lsd1抑制剂
EP3964204A1 (en) 2020-09-08 2022-03-09 Université d'Aix-Marseille Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues
WO2022171044A1 (zh) * 2021-02-09 2022-08-18 南昌弘益药业有限公司 一种氧氮杂螺环化合物、其盐型及其晶型
JP2024513260A (ja) 2021-04-08 2024-03-22 オリゾン ジェノミックス ソシエダッド アノニマ 骨髄癌処置のためのｌｓｄ１阻害剤の組み合わせ
WO2022267495A1 (zh) * 2021-06-22 2022-12-29 南昌弘益药业有限公司 含氮氧杂螺环类化合物及其应用
CN113512031B (zh) * 2021-07-01 2024-01-30 都创(上海)医药开发有限公司 一种lsd1酶抑制剂tak-418中间体化合物制备方法
GB202115017D0 (en) 2021-10-20 2021-12-01 Univ London Queen Mary Sequential treatments and biomarkers to reverse resistance to kinase inhibitors
WO2023067058A1 (en) 2021-10-20 2023-04-27 Queen Mary University Of London Sequential treatments and biomarkers to reverse resistance to kinase inhibitors
WO2023217784A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802206D0 (sv) * 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
EP2361242B1 (en) * 2008-10-17 2018-08-01 Oryzon Genomics, S.A. Oxidase inhibitors and their use
WO2010084160A1 (en) * 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
MX338041B (es) 2009-09-25 2016-03-30 Oryzon Genomics Sa Inhibidores de demetilasa-1 especificos de lisina y su uso.
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
KR101794020B1 (ko) * 2010-04-19 2017-11-06 오리존 지노믹스 에스.에이. 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도
US9181198B2 (en) 2010-07-29 2015-11-10 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
WO2012013727A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
US20140163041A1 (en) 2011-02-08 2014-06-12 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
CN107266345B (zh) * 2011-10-20 2021-08-17 奥瑞泽恩基因组学股份有限公司 作为lsd1抑制剂的(杂)芳基环丙胺化合物

Also Published As

Publication number Publication date
CA2831143C (en) 2019-05-21
JP5813855B2 (ja) 2015-11-17
WO2012135113A2 (en) 2012-10-04
PE20141322A1 (es) 2014-10-05
CN103857393B (zh) 2016-08-17
CA2831143A1 (en) 2012-10-04
US9346840B2 (en) 2016-05-24
US8853408B2 (en) 2014-10-07
US20180000805A1 (en) 2018-01-04
WO2012135113A3 (en) 2014-05-01
SG193241A1 (en) 2013-10-30
EA023143B1 (ru) 2016-04-29
US20140371176A1 (en) 2014-12-18
EP2688568A2 (en) 2014-01-29
AU2012236868B2 (en) 2015-09-17
ZA201306580B (en) 2014-05-28
KR20140036163A (ko) 2014-03-25
BR112013024502A2 (pt) 2016-12-27
ES2742805T3 (es) 2020-02-17
EP2688568B1 (en) 2019-06-19
US10064854B2 (en) 2018-09-04
US20160220547A1 (en) 2016-08-04
NZ616918A (en) 2015-06-26
US20140018393A1 (en) 2014-01-16
JP2014515013A (ja) 2014-06-26
CL2013002737A1 (es) 2014-03-28
KR101884493B1 (ko) 2018-08-01
EP2688568A4 (en) 2015-05-06
EA201391390A1 (ru) 2014-01-30
IL228248A (en) 2016-09-29
CO6771447A2 (es) 2013-10-15
AU2012236868A1 (en) 2013-04-18
BR112013024502B1 (pt) 2021-09-08
MY165620A (en) 2018-04-18
CN103857393A (zh) 2014-06-11
CR20130550A (es) 2014-03-24
US9795597B2 (en) 2017-10-24
MA35096B1 (fr) 2014-05-02
MX2013010969A (es) 2014-03-27
DOP2013000211A (es) 2014-01-31

Similar Documents

Publication Publication Date Title
MY165620A (en) Cyclopropylamines as lsd1 inhibitors
PH12017502141A1 (en) Compounds and their methods of use
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
NZ700928A (en) Dna-pk inhibitors
AU2012324803A8 (en) (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
PH12015500689B1 (en) Azaquinazoline inhibitors of atypical protein kinase c
EA201500362A1 (ru) Ингибиторы rho-киназы
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
PH12014502513A1 (en) Nampt inhibitors
MX2014013752A (es) Inhibidores de nampt.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MD20150071A2 (ro) Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
MX356813B (es) Derivados de hidantoina utiles como inhibidores de kv3.
PH12015501038A1 (en) Inhibitors of iap
MX348311B (es) Inhibidores nampt.
GEP201706687B (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
MX2014013758A (es) Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
AU2016204389A1 (en) Kinase inhibitors for the treatment of cancer
UA109932C2 (xx) Циклопропіламіни як інгібітори lsd1

Legal Events

Date Code Title Description
FG Grant or registration